Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ProSpective multIcenter observationaL Study on the Quality of Life of mCRC RAS Wild-type Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line of Treatment

NCT02624895 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02624895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02624895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ProSpective multIcenter observationaL Study on the Quality of Life of mCRC RAS Wild-type Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line of Treatment
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
December 30, 2015
Completion date
December 31, 2020
Enrollment
296 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer